Clinical-stage specialty pharmaceutical company developing therapeutics and drug delivery systems for ophthalmic diseases.
About
EyeGate Pharmaceuticals was a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The company's lead product candidate was EGP-437, which utilized a proprietary iontophoretic drug delivery system. EyeGate underwent a name change to Kiora Pharmaceuticals in November 2021.
Tags
Performance
Company Timeline
No timeline data for this period
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does EyeGate Pharmaceuticals do?
EyeGate Pharmaceuticals was a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The company's lead product candidate was EGP-437, which utilized a proprietary iontophoretic drug delivery system. EyeGate underwent a name change to Kiora Pharmaceuticals in November 2021.
How much funding has EyeGate Pharmaceuticals raised?
EyeGate Pharmaceuticals has raised a total of $45M in funding. The most recent round on record is Debt.
Where is EyeGate Pharmaceuticals headquartered?
EyeGate Pharmaceuticals is headquartered in Waltham, United States.
When was EyeGate Pharmaceuticals founded?
EyeGate Pharmaceuticals was founded in 2000.
What industry does EyeGate Pharmaceuticals operate in?
EyeGate Pharmaceuticals operates in Biotech, MedTech, HealthTech, Drug Discovery, Ophthalmology, Pharmaceuticals.
Similar Startups